IMMVF logo

Immunovia AB (publ) (IMMVF)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Immunovia AB (publ) (IMMVF) with AI Score 39/100 (Weak). Immunovia AB (publ) is a diagnostic company focused on early detection of cancer through blood-based tests. Their primary product, IMMray PanCan-d, aims to improve outcomes for pancreatic cancer patients. Market cap: 0, Sector: Healthcare.

Last analyzed: Mar 18, 2026
Immunovia AB (publ) is a diagnostic company focused on early detection of cancer through blood-based tests. Their primary product, IMMray PanCan-d, aims to improve outcomes for pancreatic cancer patients.
39/100 AI Score

Immunovia AB (publ) (IMMVF) Healthcare & Pipeline Overview

CEOJeff Borcherding
Employees9
HeadquartersLund, SE
IPO Year2019

Immunovia AB (publ) develops and commercializes blood-based diagnostic tests, primarily IMMray PanCan-d for early pancreatic cancer detection, operating in the competitive medical diagnostics market with a focus on international expansion and lung cancer research projects, while facing financial challenges reflected in negative profit margins.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 18, 2026

Investment Thesis

Immunovia AB (publ) presents a high-risk, high-reward investment opportunity centered on its IMMray PanCan-d test for early pancreatic cancer detection. The potential value driver is the successful commercialization and adoption of IMMray PanCan-d, addressing a critical unmet need in cancer diagnostics. Key catalysts include positive clinical trial results, regulatory approvals, and successful market penetration in key geographic regions. However, the company's negative profit margin of -21332.5% and gross margin of -2337.6% highlight significant financial challenges. The company's future hinges on securing additional funding and achieving profitability. Investors should closely monitor the company's cash burn rate, revenue growth, and competitive landscape.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $0.01 billion, indicating a micro-cap company with significant growth potential but also higher risk.
  • P/E ratio of -0.58, reflecting current losses and the company's focus on growth and future profitability.
  • Profit Margin of -21332.5%, highlighting the company's current financial struggles and the need for improved cost management and revenue generation.
  • Gross Margin of -2337.6%, indicating challenges in the cost of goods sold and pricing strategies.
  • Beta of 2.77, suggesting high volatility compared to the overall market, reflecting the speculative nature of the stock and its sensitivity to market fluctuations.

Competitors & Peers

Strengths

  • Proprietary IMMray PanCan-d test for early pancreatic cancer detection.
  • Focus on a critical unmet need in cancer diagnostics.
  • Expertise in proteomics and biomarker discovery.
  • International operations.

Weaknesses

  • Negative profit and gross margins.
  • Small company size with limited resources.
  • Reliance on a single product (IMMray PanCan-d).
  • Limited market penetration.

Catalysts

  • Upcoming: Positive results from ongoing clinical trials of IMMray PanCan-d.
  • Ongoing: Expansion of commercial operations into new geographic markets.
  • Ongoing: Development of new diagnostic tests for other cancers.
  • Ongoing: Strategic partnerships and collaborations with pharmaceutical companies and healthcare providers.

Risks

  • Ongoing: Intense competition from established diagnostics companies.
  • Potential: Regulatory hurdles and approval processes for diagnostic tests.
  • Potential: Reimbursement challenges from healthcare payers.
  • Ongoing: Negative profit and gross margins, requiring additional funding.
  • Potential: Technological advancements and disruptive innovations in cancer diagnostics.

Growth Opportunities

  • Expansion into New Geographic Markets: Immunovia has the opportunity to expand its commercial operations into new geographic markets, particularly in regions with high pancreatic cancer incidence rates and unmet diagnostic needs. This expansion could involve establishing partnerships with local distributors, conducting clinical trials in new regions, and obtaining regulatory approvals in new countries. Successful geographic expansion could significantly increase Immunovia's revenue and market share. Timeline: Ongoing.
  • Development of New Diagnostic Tests: Immunovia can leverage its expertise in proteomics and biomarker discovery to develop new diagnostic tests for other types of cancer and diseases. This diversification of its product portfolio would reduce its reliance on IMMray PanCan-d and create new revenue streams. The company's research projects focused on lung cancer represent a potential first step in this direction. Timeline: Ongoing.
  • Strategic Partnerships and Collaborations: Immunovia can pursue strategic partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare providers to accelerate the development and commercialization of its diagnostic tests. These partnerships could provide access to funding, expertise, and distribution channels. For example, a partnership with a pharmaceutical company developing a new pancreatic cancer drug could help to drive adoption of IMMray PanCan-d. Timeline: Ongoing.
  • Increased Awareness and Adoption of IMMray PanCan-d: Immunovia can invest in marketing and educational initiatives to increase awareness and adoption of IMMray PanCan-d among physicians and patients. This could involve presenting clinical data at medical conferences, publishing articles in peer-reviewed journals, and conducting direct-to-consumer advertising campaigns. Increased awareness and adoption of IMMray PanCan-d would drive revenue growth and improve patient outcomes. Timeline: Ongoing.
  • Leveraging AI and Machine Learning: Immunovia can integrate artificial intelligence (AI) and machine learning (ML) technologies into its diagnostic development process to improve the accuracy and efficiency of its tests. AI/ML can be used to identify new biomarkers, optimize test algorithms, and personalize diagnostic results. This would enhance the value proposition of Immunovia's tests and give it a competitive advantage. Timeline: Ongoing.

Opportunities

  • Expansion into new geographic markets.
  • Development of new diagnostic tests for other cancers.
  • Strategic partnerships and collaborations.
  • Increased awareness and adoption of IMMray PanCan-d.

Threats

  • Competition from established diagnostics companies.
  • Regulatory hurdles and approval processes.
  • Technological advancements and disruptive innovations.
  • Reimbursement challenges from healthcare payers.

Competitive Advantages

  • Proprietary IMMray PanCan-d test.
  • Expertise in proteomics and biomarker discovery.
  • Focus on early cancer detection.
  • Research projects for lung cancer.

About IMMVF

Immunovia AB (publ), established in 2007 and headquartered in Lund, Sweden, is a diagnostic company dedicated to the development and commercialization of innovative blood tests. The company's flagship product, IMMray PanCan-d, is a blood-based test designed for the early detection of pancreatic cancer, a disease known for its aggressive nature and poor prognosis when diagnosed late. Immunovia's mission is to improve survival rates and quality of life for patients by enabling earlier diagnosis and treatment interventions. Beyond pancreatic cancer, Immunovia is also engaged in research projects focused on lung cancer, indicating a broader ambition to expand its diagnostic capabilities across multiple cancer types. The company operates both in Sweden and internationally, reflecting its commitment to making its diagnostic solutions accessible to patients worldwide. Immunovia's business model centers around the development, validation, and commercialization of proprietary diagnostic tests, leveraging its expertise in proteomics and biomarker discovery. The company faces competition from established players in the diagnostics industry, as well as emerging companies developing novel cancer detection technologies. With a small team of 9 employees, Immunovia operates with a lean structure, focusing its resources on research, development, and commercialization efforts.

What They Do

  • Develop blood-based diagnostic tests.
  • Focus on early detection of pancreatic cancer.
  • Commercialize IMMray PanCan-d test.
  • Conduct research projects for lung cancer.
  • Operate in Sweden and internationally.
  • Aim to improve survival rates for cancer patients.

Business Model

  • Develop proprietary diagnostic tests.
  • Commercialize tests through direct sales and partnerships.
  • Generate revenue from test sales.
  • Invest in research and development for new tests.

Industry Context

Immunovia operates in the medical diagnostics industry, a sector experiencing rapid growth driven by technological advancements and increasing demand for early and accurate disease detection. The market for cancer diagnostics is particularly large and growing, fueled by an aging population and rising cancer incidence rates. Immunovia's focus on early pancreatic cancer detection positions it within a niche segment of this market. Competitors include companies developing liquid biopsy tests and other diagnostic modalities. The industry is characterized by intense competition, stringent regulatory requirements, and the need for continuous innovation.

Key Customers

  • Hospitals and clinics.
  • Physicians and oncologists.
  • Patients at risk of pancreatic cancer.
  • Healthcare providers.
AI Confidence: 79% Updated: Mar 18, 2026

Financials

Chart & Info

Immunovia AB (publ) (IMMVF) stock price: Price data unavailable

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMMVF.

Price Targets

Wall Street price target analysis for IMMVF.

MoonshotScore

39/100

What does this score mean?

The MoonshotScore rates IMMVF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Classification

Sector Healthcare Industry Medical - Diagnostics & Research

Latest News

Leadership: Jeff Borcherding

CEO

Jeff Borcherding serves as the CEO of Immunovia AB (publ). Information regarding his detailed career history, education, and previous roles is not available in the provided data. As the CEO, he is responsible for leading the company's strategic direction, overseeing its operations, and driving its growth initiatives. He manages a team of 9 employees.

Track Record: Information regarding Jeff Borcherding's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. His tenure at Immunovia AB (publ) cannot be determined from the given information.

IMMVF OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that Immunovia AB (publ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be subject to limited regulatory oversight and may not provide comprehensive financial disclosures. Investing in companies on the OTC Other tier carries a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ due to the potential for less transparency and liquidity.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown
Liquidity: Liquidity for IMMVF shares traded on the OTC market is likely to be limited, potentially resulting in wider bid-ask spreads and greater price volatility. The trading volume may be low, making it difficult to buy or sell large quantities of shares without significantly impacting the price. Investors should exercise caution and be prepared for potential challenges in executing trades efficiently.
OTC Risk Factors:
  • Limited liquidity and trading volume.
  • Lack of regulatory oversight and transparency.
  • Potential for price manipulation and fraud.
  • Higher risk of financial distress or bankruptcy.
  • Limited access to information and research.
Due Diligence Checklist:
  • Verify the company's financial statements and disclosures.
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's legal and regulatory compliance.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before investing.
  • Check for any history of regulatory issues or red flags.
Legitimacy Signals:
  • Company has been in operation since 2007.
  • Focus on developing diagnostic tests for cancer.
  • Commercializing IMMray PanCan-d test.
  • Presence of a CEO (Jeff Borcherding).

What Investors Ask About Immunovia AB (publ) (IMMVF)

What does Immunovia AB (publ) do?

Immunovia AB (publ) is a diagnostic company that develops and commercializes blood-based tests for the early detection of cancer, with a primary focus on pancreatic cancer. Its flagship product, IMMray PanCan-d, is designed to detect pancreatic cancer at an early stage, improving patient outcomes. The company also conducts research projects for lung cancer, indicating a broader ambition to expand its diagnostic capabilities. Immunovia operates in Sweden and internationally, aiming to make its diagnostic solutions accessible to patients worldwide.

What do analysts say about IMMVF stock?

AI analysis is pending for IMMVF. Therefore, no analyst consensus, valuation metrics, or growth considerations are currently available. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. The company's financial performance and future prospects should be carefully evaluated based on available information and industry trends.

What are the main risks for IMMVF?

The main risks for Immunovia AB (publ) include intense competition from established diagnostics companies, regulatory hurdles and approval processes for its diagnostic tests, and potential reimbursement challenges from healthcare payers. The company's negative profit and gross margins also pose a significant risk, requiring it to secure additional funding to sustain its operations. Additionally, technological advancements and disruptive innovations in cancer diagnostics could render its products obsolete.

How does Immunovia AB (publ) manage patent expiration risks?

As a diagnostic company, Immunovia AB (publ) faces risks associated with patent protection for its IMMray PanCan-d test and other diagnostic technologies. While specific details on their patent portfolio are unavailable, the company likely employs strategies such as filing patents on novel biomarkers, test algorithms, and methods of use. Managing patent expiration involves continuously innovating and developing new diagnostic solutions to maintain a competitive edge and protect its intellectual property. The company must also monitor the competitive landscape for potential patent infringement and be prepared to defend its patents if necessary.

What revenue streams does Immunovia AB (publ) have in healthcare?

Immunovia AB (publ)'s primary revenue stream is currently derived from the commercialization of its IMMray PanCan-d test for early pancreatic cancer detection. While specific revenue figures are not provided, the company generates income from the sale of this test to hospitals, clinics, and healthcare providers. As Immunovia expands its product portfolio and geographic reach, it anticipates diversifying its revenue streams through the introduction of new diagnostic tests and the establishment of partnerships with pharmaceutical companies and research institutions. The success of these efforts will be crucial for the company's long-term financial sustainability.

What are the key factors to evaluate for IMMVF?

Immunovia AB (publ) (IMMVF) currently holds an AI score of 39/100, indicating low score. Key strength: Proprietary IMMray PanCan-d test for early pancreatic cancer detection.. Primary risk to monitor: Ongoing: Intense competition from established diagnostics companies.. This is not financial advice.

How frequently does IMMVF data refresh on this page?

IMMVF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven IMMVF's recent stock price performance?

Recent price movement in Immunovia AB (publ) (IMMVF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary IMMray PanCan-d test for early pancreatic cancer detection.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Limited financial data available.
  • OTC market investments are highly speculative.
Data Sources

Popular Stocks